Amiodarone treatment of junctional ectopic tachycardia in a neonate receiving extracorporeal membrane oxygenation.
OBJECTIVE
To describe the administration of amiodarone and the resulting serum concentrations in a neonate receiving extracorporeal membrane oxygenation (ECMO).


METHODS
A 3463 g, 38 week gestational age male diagnosed with tetralogy of Fallot developed junctional ectopic tachycardia (JET) and required ECMO support following cardiac surgery. The patient continued to show JET despite cooling, pacing, and intravenous amiodarone infusion, with the dose initiated at 10 microg/kg/min. Sinus rhythm was achieved following 5 days of treatment, additional amiodarone boluses, and an increase in the infusion rate to 20 microg/kg/min. Two serum concentrations of amiodarone were obtained during therapy. On day 4, the concentration was 0.9 mg/L at the 20 microg/kg/min infusion rate; a bolus dose of 5 mg/kg was administered 1 hour later. The serum concentration the following day, with the infusion rate unchanged, was 2 mg/L.


CONCLUSIONS
ECMO is used increasingly postoperatively in patients with congenital cardiac abnormalities. The incidence of JET following repair of tetralogy of Fallot is 22%. Despite the minimal information on the pharmacokinetics of amiodarone in neonates, it has been used in doses up to 20 microg/kg/min for the treatment of postoperative JET. As of August 25, 2006, we found no reports describing its dosage and use in patients undergoing ECMO.


CONCLUSIONS
The delivery of amiodarone to a patient receiving ECMO may be complicated by the administration of large blood volumes, circuit changes, and binding to the circuit. Neonates receiving ECMO may require larger amiodarone doses to achieve a therapeutic effect. Further investigation is required to define the pharmacokinetics and pharmacodynamics of amiodarone in neonates receiving ECMO.
Kendrick
Jennifer G
JG
Pharmacy Department, British Columbia's Children's Hospital, Vancouver, British Columbia, Canada.
Macready
John J
JJ
Kissoon
Niranjan
N
D000638:Amiodarone / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use*; D015199:Extracorporeal Membrane Oxygenation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D013613:Tachycardia, Ectopic Junctional / Q000097:blood* / Q000188:drug therapy*
D000638:Amiodarone